Skip to content Skip to footer
Subscribe Now
A Complete Account of EMA Approvals in 2024
INSIGHTS+

A Complete Account of EMA Approvals in 2024

Shots:  In 2024, EMA approved around 53 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, vaccines, diagnostic agents, pneumology, nephrology, hepatology, ophthalmology, and endocrinology  PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, &…
March 6, 2025

Read more

ThoughtSpot_Igor Zagradanin5
THOUGHTSPOT

Preparing for Your First Sperm Donation Appointment

Donating sperm is a significant decision that assists numerous individuals and couples in fulfilling their wish to have children. Nonetheless, research on sperm banks reveals a crucial problem: insufficient donors from diverse backgrounds, posing difficulties for recipients seeking compatible matches from varied backgrounds. If you're considering becoming a donor, adequately preparing for your first visit can make…
July 23, 2024

Read more

VIEWPOINTS_Nathan McCutcheon_2023
VIEWPOINTS

Nathan McCutcheon shares highlights of Qpex Biopharma’s acquisition by Shionogi

Shots: Nathan McCutcheon, President, and Chief Executive Officer of Shionogi, shares the highlights of the recent acquisition of Qpex Biopharma by Shionogi  Nathan believes that Qpex’s specialized expertise and extensive experience in chemistry and molecular design are sure to strengthen and be useful for the combined antibiotic pipeline  The acquisition provides Shionogi exclusive development, manufacturing,…
October 16, 2023

Read more

VIEWPOINTS_Mary Rodgers_2023
VIEWPOINTS

Mary Rodgers, Principal Research Scientist at Abbott Shares Insights on its Partnership with CLIMADE Consortium to Predict Disease Outbreaks Caused by Climate Change

Shots:Mary talked about Abbott's partnership Climate Amplified Disease and Epidemics (CLIMADE) consortium will use data science to predict, track and control diseases that may be amplified by climate changeShe then spoke about how Abbott and its partners in the Abbott Pandemic Defense Coalition will provide viral sequencing and testing data as part of…
August 3, 2023

Read more

Viewpoints_Dr. Bill La Via
VIEWPOINTS

Dr. Bill La Via, Medical Director at Sanofi Shares Insights from the Findings that Support the Need of Protecting Infants from Respiratory Syncytial Virus (RSV)

Shots:Bill spoke about Respiratory Syncytial Virus and how it can severely affect infants' healthBill also talked about the 14 studies on RSV published in the Journal of Infectious Diseases (JID)The interview gives an understanding of how Sanofi’s vision to develop innovative solutions to help reduce the burden of RSV on infants, families,…
November 9, 2022

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]